Search Results - "TAKIMOTO, H"

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma by Advani, Ranjana, Flinn, Ian, Popplewell, Leslie, Forero, Andres, Bartlett, Nancy L, Ghosh, Nilanjan, Kline, Justin, Roschewski, Mark, LaCasce, Ann, Collins, Graham P, Tran, Thu, Lynn, Judith, Chen, James Y, Volkmer, Jens-Peter, Agoram, Balaji, Huang, Jie, Majeti, Ravindra, Weissman, Irving L, Takimoto, Chris H, Chao, Mark P, Smith, Sonali M

“…An antibody to CD47 used in combination with rituximab induced responses in half of a small group of patients with refractory B-cell lymphoma. Inhibiting the…”
Get full text

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies by Chao, Mark P, Takimoto, Chris H, Feng, Dong Dong, McKenna, Kelly, Gip, Phung, Liu, Jie, Volkmer, Jens-Peter, Weissman, Irving L, Majeti, Ravindra

“…In recent years, immunotherapies have been clinically investigated in AML and other myeloid malignancies. While most of these are focused on stimulating the…”
Get full text

Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes by ATTAR, Ricardo M, TAKIMOTO, Chris H, GOTTARDIS, Marco M

“…The understanding of the key role that androgens play on the normal and pathological physiology of the prostate guided the development of different therapies…”
Get full text

Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab by KHAMBATA-FORD, Shirin, GARRETT, Christopher R, TAN, Benjamin R, KRISHNAMURTHI, Smitha S, BURRIS, Howard A, POPLIN, Elizabeth A, HIDALGO, Manuel, BASELGA, Jose, CLARK, Edwin A, MAURO, David J, MEROPOL, Neal, BASIK, Mark, HARBISON, Christopher T, SHUJIAN WU, WONG, Tai W, XIN HUANG, TAKIMOTO, Chris H, GODWIN, Andrew K

“…The antiepidermal growth factor receptor (EGFR) antibody cetuximab shows activity in multiple epithelial tumor types; however, responses are seen in only a…”
Get full text

Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas by MAKI, Robert G, D'ADAMO, David R, TAKIMOTO, Chris H, KRAFT, Andrew S, ELIAS, Anthony D, BROCKSTEIN, Bruce, BLACHERE, Nathalie E, EDGAR, Mark A, SCHWARTZ, Lawrence H, QIN, Li-Xuan, ANTONESCU, Cristina R, SCHWARTZ, Gary K, KEOHAN, Mary L, SAULLE, Michael, SCHUETZE, Scott M, UNDEVIA, Samir D, LIVINGSTON, Michael B, COONEY, Matthew M, HENSLEY, Martee L, MITA, Monica M

“…PURPOSE Since activity of sorafenib was observed in sarcoma patients in a phase I study, we performed a multicenter phase II study of daily oral sorafenib in…”
Get full text

A scoping review of epidemiological studies of sugar intake in Asian countries: comparison of dietary assessment methodology by Fujiwara, A., Omura, Y., Oono, F., Sugimoto, M., Sasaki, S., Takimoto, H.

“…Inclusion criteria were: published in English; full-text articles in peer-reviewed journals; targeting habitants in Asian countries; estimating self-selected…”
Get full text

Spontaneous oral tumours in 18 rabbits (2005–2015) by Miwa, Y., Nakata, M., Takimoto, H., Chambers, J. K., Uchida, K.

“…This retrospective study of a series of 18 cases aimed to describe the clinical and pathological findings of oral tumours in rabbits, as there have been few…”
Get full text

Spontaneous intranasal tumours in rabbits: 7 cases (2007‐2019) by Miwa, Y., Nakata, M., Takimoto, H., Chambers, J. K., Uchida, K.

“…Summary Objectives Neoplasms that arise in the nasal cavity are reported infrequently in rabbits. This case series aims to review and determine the clinical…”
Get full text

Perceived body size and desire for thinness of young Japanese women: a population-based survey by Hayashi, F., Takimoto, H., Yoshita, K., Yoshiike, N.

“…The present study describes findings in relation to perceived body size and ‘desire for thinness’ by age and residential areas (‘metropolitan areas’, ‘large…”
Get full text

Heat shock proteins: a potential anticancer target by Sankhala, Kamalesh K, Mita, Monica M, Mita, Alain C, Takimoto, Chris H

“…Heat shock proteins (Hsp) are highly conserved proteins and their expression is dependent on the level of various cellular stresses. Hsp work as a molecular…”
Get more information

Dietary Genistein Inhibits Metastasis of Human Prostate Cancer in Mice by LAKSHMAN, Minalini, LI XU, ANANTHANARAYANAN, Vijayalakshmi, COOPER, Joshua, TAKIMOTO, Chris H, HELENOWSKI, Irene, PELLING, Jill C, BERGAN, Raymond C

“…Dietary genistein has been linked to lower prostate cancer (PCa) mortality. Metastasis is the ultimate cause of death from PCa. Cell detachment and invasion…”
Get full text

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies by Goel, Sanjay, Mita, Alain C, Mita, Monica, Rowinsky, Eric K, Chu, Quincy S, Wong, Nancy, Desjardins, Christopher, Fang, Fang, Jansen, Mendel, Shuster, Dale E, Mani, Sridhar, Takimoto, Chris H

“…Purpose: Eribulin mesylate (E7389), a non-taxane microtubule dynamics inhibitor, is a structurally simplified, synthetic analogue of halichondrin B that acts…”
Get full text

Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer by SIU, Lillian L, AWADA, Ahmad, TAKIMOTO, Chris H, PICCART, Martine, SCHWARTZ, Brian, GIANNARIS, Tom, LATHIA, Chetan, PETRENCIUC, Oana, MOORE, Malcolm J

“…Background: With its potent inhibitory effects against Raf-1 kinase and vascular endothelial growth factor receptor-2, sorafenib is a novel oral anticancer…”
Get full text

Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients With Solid Tumors by GREM, Jean L, MORRISON, Geraldine, NECKERS, Len, WILSON, Richard H, GUO, Xiao-Du, AGNEW, Elizabeth, TAKIMOTO, Chris H, THOMAS, Rebecca, SZABO, Eva, GROCHOW, Louise, GROLLMAN, Frank, HAMILTON, J. Michael

“…To determine the clinical toxicities of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) given as a 1-hour infusion daily for 5 days every 3 weeks. Nineteen…”
Get full text

Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing by Nikanjam, Mina, Stewart, Clinton F., Takimoto, Chris H., Synold, Timothy W., Beaty, Orren, Fouladi, Maryam, Capparelli, Edmund V.

“…Purpose To characterize the determinants of variability for oxaliplatin pharmacokinetics including age, renal function, and hepatic function in children and…”
Get full text

Numerical Simulations of Dry and Wet Deposition over Simplified Terrains by Michioka, T., Takimoto, H., Ono, H., Sato, A.

“…To evaluate the deposition amount on a ground surface, mesoscale numerical models coupled with atmospheric chemistry are widely used for larger horizontal…”
Get full text

Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function by MITA, Alain C, SWEENEY, Christopher J, MOLPUS, Kathleen, LATZ, Jane E, SIMMS, Lorinda, CHAUDHARY, Ajai K, JOHNSON, Robert D, ROWINSKY, Eric K, TAKIMOTO, Chris H, BAKER, Sharyn D, GOETZ, Andrew, HAMMOND, Lisa A, PATNAIK, Amita, TOLCHER, Anthony W, VILLAHNA-CALERO, Mtguel, SANDLER, Alan, CHAUDHURI, Tuhin

“…This phase I study was conducted to determine the toxicities, pharmacokinetics, and recommended doses of pemetrexed in cancer patients with normal and impaired…”
Get full text

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group by GIBBONS, Joseph, EGORIN, Merrill J, PAVLICK, Anna, LENZ, Heinz-Josef, FLICK, Susan M, REYNOLDS, Sherrie, LAGATTUTA, Theodore F, PARISE, Robert A, YANFENG WANG, MURGO, Anthony J, IVY, S. Percy, REMICK, Scot C, RAMANATHAN, Ramesh K, PINGFU FU, MULKERIN, Daniel L, SHIBATA, Stephen, TAKIMOTO, Chris H. M, MANI, Sridhar, LORUSSO, Patricia A, GREM, Jean L

“…This study was undertaken to determine the safety, dose-limiting toxicities (DLT), maximum-tolerated dose (MTD), and pharmacokinetics of imatinib in cancer…”
Get full text

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group by RAMANATHAN, Ramesh K, EGORIN, Merrill J, POTTER, Douglas M, BELANI, Chandra P, HAYES, Michael J, BIN PENG, IVY, S. Percy, TAKIMOTO, Chris H. M, REMICK, Scot C, DOROSHOW, James H, LORUSSO, Patricia A, MULKERIN, Daniel L, GREM, Jean L, HAMILTON, Anne, MURGO, Anthony J

“…To develop dosing guidelines and to evaluate the pharmacokinetics of imatinib in patients with liver dysfunction (LD). Patients (N = 89) with varying solid…”
Get full text

Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function by TAKIMOTO, Chris H, GRAHAM, Martin A, SYNOLD, Timothy W, DOROSHOW, James H, HAMILTON, Anne, MULKERIN, Daniel L, IVY, Percy, EGORIN, Merrill J, GREM, Jean L, LOCKWOOD, Graham, NG, Chee M, GOETZ, Andrew, GREENSLADE, Dennis, REMICK, Scot C, SHARMA, Sunil, MANI, Sridhar, RAMANATHAN, Ramesh K

“…Purpose: To characterize the pharmacokinetics and pharmacodynamics of oxaliplatin in cancer patients with impaired renal function. Experimental Design:…”
Get full text